03/22/23 7:00 AMNasdaq : OCS Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful ListingOculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that it will ring the Nasdaq opening bell today to celebrate its public listing on theRHEA-AIvery positive
03/16/23 9:45 AMNasdaq : OCS clinical trialOculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE TrialCompleted enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval. If approved, OCS-01 has the potential to become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery. SignificantRHEA-AIneutral
